Cargando…
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SC...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614195/ https://www.ncbi.nlm.nih.gov/pubmed/36719157 http://dx.doi.org/10.2215/CJN.05080422 |
_version_ | 1783605575983038464 |
---|---|
author | Donovan, Killian Herrington, William G. Paré, Guillaume Pigeyre, Marie Haynes, Richard Sardell, Rebecca Butterworth, Adam S. Folkersen, Lasse Gustafsson, Stefan Wang, Qin Baigent, Colin Mälarstig, Anders Holmes, Michael V. Staplin, Natalie |
author_facet | Donovan, Killian Herrington, William G. Paré, Guillaume Pigeyre, Marie Haynes, Richard Sardell, Rebecca Butterworth, Adam S. Folkersen, Lasse Gustafsson, Stefan Wang, Qin Baigent, Colin Mälarstig, Anders Holmes, Michael V. Staplin, Natalie |
author_sort | Donovan, Killian |
collection | PubMed |
description | BACKGROUND: Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SCALLOP consortium data on 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically-predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), of any non-atherosclerotic cardiovascular disease (n=12,652), and of non-cardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309). RESULTS: We identified 34 independent variants for circulating FGF-23 which formed a validated genetic score. There were no associations between genetically-predicted FGF-23 and any of the cardiovascular or non-cardiovascular outcomes. In UK Biobank, the odds ratio for any atherosclerotic cardiovascular disease per 1-SD higher genetically-predicted logFGF-23 was 1.03 (95% confidence interval [CI] 0.98-1.08), and for any non-atherosclerotic cardiovascular disease was 1.01 (0.94-1.09). The odds ratios in the case-control consortia were 1.00 (0.97-1.03) for coronary artery disease, 1.01 (0.95-1.07) for stroke, and 1.00 (0.95-1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalties. CONCLUSION: Genetically predicted FGF-23 levels are not associated atherosclerotic and non-atherosclerotic cardiovascular diseases, suggesting no important causal link. |
format | Online Article Text |
id | pubmed-7614195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76141952023-02-17 Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study Donovan, Killian Herrington, William G. Paré, Guillaume Pigeyre, Marie Haynes, Richard Sardell, Rebecca Butterworth, Adam S. Folkersen, Lasse Gustafsson, Stefan Wang, Qin Baigent, Colin Mälarstig, Anders Holmes, Michael V. Staplin, Natalie Clin J Am Soc Nephrol Article BACKGROUND: Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help control for such confounding. METHODS: SCALLOP consortium data on 19,195 participants were used to generate an FGF-23 genetic score. Data from 337,448 UK Biobank participants were used to estimate associations between higher genetically-predicted FGF-23 concentration and the odds of any atherosclerotic cardiovascular disease (n=26,266 events), of any non-atherosclerotic cardiovascular disease (n=12,652), and of non-cardiovascular diseases previously linked to FGF-23. Measurements of carotid intima-media thickness and left ventricular mass were available in a subset. Associations with cardiovascular outcomes were also tested in three large case-control consortia: CARDIOGRAMplusC4D (coronary artery disease, n=181,249 cases), MEGASTROKE (stroke, n=34,217), and HERMES (heart failure, n=47,309). RESULTS: We identified 34 independent variants for circulating FGF-23 which formed a validated genetic score. There were no associations between genetically-predicted FGF-23 and any of the cardiovascular or non-cardiovascular outcomes. In UK Biobank, the odds ratio for any atherosclerotic cardiovascular disease per 1-SD higher genetically-predicted logFGF-23 was 1.03 (95% confidence interval [CI] 0.98-1.08), and for any non-atherosclerotic cardiovascular disease was 1.01 (0.94-1.09). The odds ratios in the case-control consortia were 1.00 (0.97-1.03) for coronary artery disease, 1.01 (0.95-1.07) for stroke, and 1.00 (0.95-1.05) for heart failure. In those with imaging, logFGF-23 was not associated with carotid or cardiac abnormalties. CONCLUSION: Genetically predicted FGF-23 levels are not associated atherosclerotic and non-atherosclerotic cardiovascular diseases, suggesting no important causal link. 2023-01-01 /pmc/articles/PMC7614195/ /pubmed/36719157 http://dx.doi.org/10.2215/CJN.05080422 Text en https://creativecommons.org/licenses/by/4.0/Open Access For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising. (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Article Donovan, Killian Herrington, William G. Paré, Guillaume Pigeyre, Marie Haynes, Richard Sardell, Rebecca Butterworth, Adam S. Folkersen, Lasse Gustafsson, Stefan Wang, Qin Baigent, Colin Mälarstig, Anders Holmes, Michael V. Staplin, Natalie Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title | Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title_full | Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title_fullStr | Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title_full_unstemmed | Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title_short | Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study |
title_sort | fibroblast growth factor-23 and risk of cardiovascular diseases: a mendelian randomization study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614195/ https://www.ncbi.nlm.nih.gov/pubmed/36719157 http://dx.doi.org/10.2215/CJN.05080422 |
work_keys_str_mv | AT donovankillian fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT herringtonwilliamg fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT pareguillaume fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT pigeyremarie fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT haynesrichard fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT sardellrebecca fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT butterworthadams fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT folkersenlasse fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT gustafssonstefan fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT wangqin fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT baigentcolin fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT malarstiganders fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT holmesmichaelv fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy AT staplinnatalie fibroblastgrowthfactor23andriskofcardiovasculardiseasesamendelianrandomizationstudy |